REG - Argent Biopharma Ltd - PDMR Notification
10/04/2024 16:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240410:nRSJ0885Ka&default-theme=true
RNS Number : 0885K Argent Biopharma Limited 10 April 2024
Argent BioPharma Ltd
PDMR Notification
10 April 2024
ASX, LSE: RGT
Argent BioPharma Ltd ('Argent BioPharma' or 'the Company') wishes to advise
that the following Persons Discharging Managerial Responsibilities (PDMR) have
dealt with shares in Argent BioPharma, and this notification is made in
accordance the UK Market Abuse Regulations.
1 Details of the person discharging managerial responsibilities/person closely
associated
(a) Name Amir Polak
2 Reason for the notification
(a) Position Chief Pharmaceutical Development Officer
(b) Initial notification/amendment Initial
(c) If amendment: reason n/a
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
Full name of entity Argent BioPharma Limited
Legal Entity Identifier Code 213800HRE3FQJ6RK4H10
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; (iv) each place
where transactions have been conducted
(a) Description of the financial instrument, type of instrument Fully Paid Ordinary Shares
(b) Identification Code (ISIN) AU0000326647
(c) Nature of transaction Disposal of Shares
(d) Currency Price Volume Total
AUD 0.43 200 86.00
AUD 0.43 3,300 1,419.00
AUD 0.44 2,000 880.00
Aggregated information
AUD 5,500 2,385.00
(e) Date of transaction 8-10 April 2024
(f) Place of transaction On Market
-Ends-
Authorised for release by the Company Secretary, for further information
please contact:
Argent BioPharma Argent BioPharma
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6382 3390 +61 8 6382 3390
info@argentbiopharma.co.uk (mailto:info@argentbiopharma.co.uk) info@argentbiopharma.co.uk (mailto:info@argentbiopharma.co.uk)
UK IR/PR Advisers UK Brokers
IFC Advisory Oberon Capital
Graham Herring / Tim Metcalfe / Zach Cohen Aimee McCusker / Adam Pollock
+44 203 934 6630 +44 203 179 5300
argentbiopharma@investor-focus.co.uk aimeemccusker@oberoninvestments.com
(mailto:argentbiopharma@investor-focus.co.uk) (mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
(mailto:adampollock@oberoninvestments.com)
About Argent BioPharma
Argent BioPharma is dedicated to meeting unmet medical needs by combining
PolyPharmacology and Nanotechnology, aspiring to be a renowned global leader
in the biopharmaceutical sector. Our mission centres on researching and
developing ground-breaking treatments for worldwide health issues, guided by
strategic principles such as pioneering life science advancements, ensuring
global access, fostering continuous innovation, and striving for industry
leadership.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHZZGMDKGLGDZM